Institution
University of Puerto Rico, Medical Sciences Campus
Education•San Juan, Puerto Rico, United States•
About: University of Puerto Rico, Medical Sciences Campus is a education organization based out in San Juan, Puerto Rico, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 1711 authors who have published 1496 publications receiving 27756 citations.
Papers published on a yearly basis
Papers
More filters
••
03 Jul 2019
TL;DR: It is demonstrated that auranofin prevents pancreatic ductal adenocarcinoma progression using multiple models and suggests inhibition of Txnrd1 and HIF-1α as possible mechanisms of action, and TxNrd1 as a biomarker of resistance.
Abstract: Background Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and HIF-1α. Methods In vitro sensitivity of human prevent pancreatic ductal adenocarcinoma cell lines was determined based on IC50. Western blot assays were used to interrogate mechanisms of apoptosis and resistance. Ex vivo live tissue slice assays of xenografts allowed for testing of a larger number of PDX samples with high efficiency. In vivo prevent pancreatic ductal adenocarcinoma orthotopic mouse models using MiaPaCa-2 Luc + cells were designed to determine optimal dose and antitumor effect. Results We found that 10 of 15 tested prevent pancreatic ductal adenocarcinoma cell lines were sensitive to auranofin based on IC50s below 5 μmol/L. Ex vivo tissue growth inhibition greater than 44% was observed for 13 PDX tissue cases treated with 10 μmol/L auranofin. High Txnrd1 expression was observed for resistant cell lines. In vivo studies showed 15 mg/kg IP as the optimal dose with absence of gross solid organ metastasis up to 13 weeks post-treatment (median survival 8 and 12 weeks, respectively; P = .0953). Conclusions We have demonstrated that auranofin prevents prevent pancreatic ductal adenocarcinoma progression using multiple models. Our study suggests inhibition of Txnrd1 and HIF-1α as possible mechanisms of action, and Txnrd1 as a biomarker of resistance. Based on these data, an off-label Phase 0 clinical trial with this FDA-approved drug should be considered for patients with pancreatic cancer.
11 citations
••
TL;DR: In this article, the authors examined the relationship between childhood sexual abuse and adult drug use among low-income urban Puerto Rican women, and found that the increased rates of drug use were associated with greater abuse severity, abuse by a family member, and increased abuse duration.
Abstract: SUMMARY This study examines the relationship between childhood sexual abuse and adult drug use among low-income urban Puerto Rican women. Interviews were conducted with 718 women, 408 involved in drug use and a comparison group of 310 non drug-users. Results demonstrate a strong association between childhood sexual abuse and adult drug use. The impact of childhood sexual abuse was greater for women reporting greater abuse severity, abuse by a family member, and increased abuse duration. Findings support a direct effects model of childhood sexual abuse on adult drug use. The increased rates of drug use among victims of childhood sexual abuse did not appear to be mediated by other childhood maltreatment or family background factors. Implications for practice and research are discussed.
11 citations
••
TL;DR: Findings indicate that both channel gating and conductance involve conformational changes in extracellular regions of the acetylcholine receptor.
11 citations
••
University of California, Los Angeles1, Wake Forest University2, Veterans Health Administration3, Oklahoma Medical Research Foundation4, Hanyang University5, University of Granada6, University of Alabama at Birmingham7, Del Rosario University8, University of California, San Francisco9, Medical University of South Carolina10, University of Southern California11, University of Oklahoma12, Mayo Clinic13, Johns Hopkins University14, Northwestern University15, University of Texas Health Science Center at Houston16, Boston Children's Hospital17, University of Puerto Rico, Medical Sciences Campus18, National Defense Medical Center19, Seoul National University20, King's College London21
TL;DR: Genotyped DNA samples from 15,706 SLE patients and healthy matched controls from four different ancestral groups to correlate polymorphisms of genes of the leptin pathway to risk for SLE found that although several SNPs showed weak associations, those associations did not remain significant after correction for multiple testing.
11 citations
••
TL;DR: In this cohort, patients who did not achieve the 2019 EULAR/ACR criteria accrued less damage, suggesting that these criteria could allow us to identify a subset of patients with more severe disease than previous criteria.
Abstract: OBJECTIVE To determine the difference in outcomes in patients who achieved or did not achieve the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria. METHODS Patients from the LUpus in MInorities, NAture versus nurture (LUMINA) cohort were included. For these analyses, we compared those patients who achieved the 2019 EULAR/ACR criteria any time during follow-up to those who did not. The predefined outcomes were the last Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) scores and survival. Univariable and multivariable negative binomial regression models were performed; adjustment models were based on a forward selection process. RESULTS In total, 98 of 640 patients never achieved the 2019 EULAR/ACR criteria. There was no difference in mean baseline SDI score among the patients who did not achieve the criteria compared to those who did. Conversely, the mean ± SD SDI score at last visit was lower for those who never achieved the criteria (1.2 ± 1.7 versus 2.0 ± 2.3, P = 0.0004). In the final adjusted model, the SDI score at last visit was 31% lower for those who never achieved the criteria (P = 0.0077). These patients were also more likely to survive, but this was not statistically significant. CONCLUSION In our cohort, patients who did not achieve the 2019 EULAR/ACR criteria accrued less damage, suggesting that these criteria could allow us to identify a subset of patients with more severe disease than allowed by previous criteria.
11 citations
Authors
Showing all 1734 results
Name | H-index | Papers | Citations |
---|---|---|---|
Martin C. Mihm | 109 | 611 | 48762 |
Helmut Kettenmann | 104 | 380 | 40211 |
Howard E. Gendelman | 101 | 567 | 39460 |
Glorisa Canino | 81 | 340 | 28559 |
John D. Meeker | 71 | 326 | 16422 |
Kathleen Puntillo | 61 | 176 | 16201 |
Luis M. Vilá | 61 | 247 | 12798 |
Gregory J. Quirk | 61 | 118 | 25677 |
Miles F. Wilkinson | 57 | 163 | 10617 |
Julie K. Andersen | 56 | 176 | 12638 |
Kaumudi Joshipura | 54 | 143 | 13944 |
Mark W. Miller | 54 | 257 | 12825 |
Anthony Auerbach | 48 | 130 | 6572 |
Cynthia Garcia Coll | 45 | 108 | 10664 |
Dean Falk | 41 | 133 | 6200 |